New data from an ongoing post-marketing study in nearly 45,000 people with non-valvular atrial fibrillation (NVAF) confirm the safety profile of XARELTO® (rivaroxaban) was generally consistent with the findings observed in ROCKET AF, the Phase 3 study that supported the approval of the medicine for prevention of stroke in patients with NVAF.